



Benzothiazole analogues and their biological aspects: A Review

Jyoti V Popli^{a*}, Manoj R Kumbhare^a, Ajay R Surana^b, Mrunal R Bhalerao^a & Pranay A Agrawal^a

^a Department of Pharmaceutical Chemistry, S.M.B.T College of Pharmacy, Dhamangaon, Taluka: Igatpuri, District Nashik 422 403, India

^b Department of Pharmacognosy, S.M.B.T College of Pharmacy, Dhamangaon, Taluka: Igatpuri, District Nashik 422 403, India

E-mail: jyotipopli97@gmail.com

Received 13 May 2021; accepted (revised) 23 September 2021

Heterocyclic compounds analogues have attracted strong interest in medicinal chemistry due to their pharmacological properties. Benzothiazole belongs to the heterocyclic class of bicyclic compounds. It is a combination of two rings six membered and five membered and both the rings are responsible for the therapeutic activity. Different methods are used to synthesize benzothiazole compounds and have been found to have numerous biological activities like – anticancer, antimicrobial, anti-inflammatory, anti-leishmanial, antidiabetic activity. This review is mainly an attempt to present the work reported in literature on pharmacological activity of benzothiazole compounds.

Keywords: Heterocyclic, antimicrobial, anticancer, anti-inflammatory

The chemistry and biological study of heterocyclic compounds has been a thought-provoking field for a long time in medicinal chemistry. A heterocyclic compound is one which contains cyclic ring made up of more than one kind of atom. In some cyclic compounds like benzene, naphthalene, cyclohexanol, etc. The ring made up of only carbon atom is called homocyclic rings. If ring contains other kind of atom in addition to carbon atom like N, S, O, etc in ring system are referred to as heterocyclic compounds¹. In several compounds, benzene is fused with 5-membered heterocyclic system such as indole, benzothiazole, benzimidazole, benzoxazole which have been synthesized and extensively because of their pharmacological activity² (Figure 1).

Overview

Hantzsch and Waber in 1887 first described thiazolein and later on its structure was confirmed by Popp in 1889³. Benzothiazole are important class of heterocycles which functions as an exclusive and adaptable scaffold for experimental drug design⁴. The ring system in which benzene ring is fused to 4, 5 position of thiazole ring is titled as benzothiazole and is completely planar. The various positions on benzothiazole ring are numbered in manner indicated with Sulphur having the priority over other family members. Benzothiazole rarely occur in various marine or terrestrial natural compounds which have useful biological activities⁵.

Benzothiazole derivatives have attracted continuing interest due to their biological activities viz. anticancer⁶,

antimicrobial⁷, anticonvulsant⁸, antiviral⁹, antitubercular¹⁰, antimalarial¹¹. Recently benzothiazole have been appraised as potential amyloid binding diagnostic agent in neurodegenerative disease^{12,13}, inhibitors of coenzyme A-9 desaturase¹⁴, plant protectants¹⁵ and photographic sensitizers¹⁶. Being a heterocyclic, benzothiazole finds use in research as a starting material for the synthesis of large, usually bioactive structure. Its aromaticity makes it relatively stable, as a heterocycle, it has reactive sites, which allows for functionalization. Benzothiazole is a colourless, slightly viscous liquid with m.p.2°C and b.p.237-238°C. The density of benzothiazole is 1.24 g/ml and molecular mass is 135.19 g/mol. It is used in industry and research¹⁷.

Chemistry

In 1887, 2- substituted benzothiazole was synthesized by A.W Hoffmann because of diversified activity as well as simple cyclization mechanism¹⁸. Traditional methods for preparation of the benzothiazole framework




Figure 1 — Fused heterocyclic compound




Figure 2 — General scheme for synthesis of benzothiazole




Figure 3 — Synthesis of benzothiazole aryl amide and aryl urea derivative

include condensation of 2-aminothiophenol with substituted nitriles, aldehyde, carboxylic acid or esters¹⁹. Another route for preparation of benzothiazole moiety is employing the Jacobson's cyclization of thiabenzanilides²⁰. A number of catalyst are use for the reaction namely Br, I₂, ZrOCl₂.8 H₂O, copper oxide, etc. and many more can be efficiently used to prepare benzothiazole derivative²¹ (Figure 2).

Cuputo *et al.* (2011) synthesized two sets of benzothiazole derivatives having aryl amide substitution on C-2 carbon atom or an aryl urea substitution. In synthesized compounds some of them showed there in vitro anticancer activity²² (Figure 3).

Venkatesh and Tiwari (2011) synthesized benzothiazole guanidine propanoic acid derivatives and evaluated for their cytotoxic activity against the HeLa cell lines and antimicrobial activity²³ (Figure 4).

Pharmacological Activities

Benzothiazole core is highly important scaffold for drug development because has demonstrated wide

spectrum of activities. Important medicinal activities associated with the class of compounds are:

Antimicrobial activity

Microbes are the causative agent for various types of disease such as pneumonia, amoebiasis, typhoid, malaria, cough, TB, influenza, AIDS²⁴. Infectious disease caused by bacteria affects millions of people and are leading cause of death²⁵. BTA is one the most versatile class of compound against microbes. Verma *et al.* carried out the synthesis, characterization and antimicrobial activity of benzothiazole derivatives and the synthesized compounds showed moral antibacterial activity²⁶ (3). Sahu *et al.* synthesized 4H pyrimidobenzothiazole derivative and evaluated their activity against gram positive and gram negative bacteria: Staphylococcus aureus, Pseudomonas aeruginosa, S. typhi, E.coli²⁷ (4) Nitendra K.S *et al.* synthesized hydrazine BTA derivative against four pathogenic bacterial strain Bacillus Subtilis, E.coli, Klebsiella pneumonia and pseudomonas alkaligenes and fungal strains include Aspergillus Niger, Rhizopusoryzae and Candida Albicans²⁸ (5) (Figure 5).

Haroun (2018) and coworkers synthesized iminobenzothiazole derivative and evaluated for their antimicrobial activity and all synthesized compounds exhibited better activity compared to the standard drug ampicillin²⁹ (6). Benzothiazole sulphonamide conjugate were synthesized and screened for antimicrobial activity. The compound exhibited favorable activity against different fungal and bacterial strains with MIC values ranging from 15.5-31.25 µ/mL (7a). The presence of electron withdrawing group like F, Cl, and NO₂ at 6- position on 2- amino benzothiazole showed significant antibacterial, antifungal activity³⁰ (7b) (Figure 6).




Figure 6 — Analogues of BTA as antimicrobial agent




Figure 7 — Analogues of BTA as anticancerous agent

Antiviral activity

Viruses are the obligate intracellular parasites. Their replication depends totally on synthetic processes of the host cell. Effective antiviral agents inhibit virus-specific replicate events or preferentially

inhibit virus-directed rather than host cell directed nucleic acid or protein synthesis.

Verma *et al.* synthesized 5-azobenzothiazole pyrimidine conjugated compounds and evaluated for hepatitis C virus and showed their high, good potency




Figure 8 — Analogues of BTA as anticancerous agent




Figure 9 — Analogues of BTA as antiviral agent

and excellent plasma exposure and bioavailability³⁷ (13). Akhtar *et al.* investigated a series of new benzothiazole analogues and showed their effect on leukemia cells³⁸ (14) (Figure 9).

Nagaranjan *et al.* synthesized benzothiazole sulphonamide analog which shows good antiviral activity with good bioavailability³⁹ (15) (Figure 10).

Anti-inflammatory activity

Inflammatory diseases are widely prevalent throughout the world and inflammation remains a common as well as often poorly controlled disease, which can be life threatening in extreme form of allergy, autoimmune diseases and rejection of transplanted organs, and similar chronic inflammation has been found to mediate a wide variety of disease includes cardiovascular diseases, cancer, diabetes, arthritis, AD, pulmonary diseases⁴⁰. NSAIDs have been used for the treatment of ailments such as pain, fever, inflammation. They act by two different mechanisms: a direct contact mechanism on the gastro intestinal mucosa and systemic action appearing after intravenous dosing⁴¹. Viegas and Junior *et al.* in 2007 synthesized, characterized and evaluated their antiinflammatory activity of pyrazolones and pyrazolinones for their excellent activity⁴² (16) (Figure 11).




Figure 10 — Analogues of BTA as antiviral agent




Figure 11 — BTA as anti-inflammatory

Kumar *et al.* synthesized benzothiazole conjugated with spiroindoline i.e. chloroindolybenzothiazole analog that exhibited most potent anti-inflammatory activity [72% oedema inhibition⁴³ (17). Singh *et al.* (1986) synthesized pyrazole derivative and screened their anti-inflammatory activity⁴⁴ (18) (Figure 12).





Figure 12 — Analogues of BTA as anti-inflammatory agent

Anti- HIV activity

Acquired HIV (Human Immunodeficiency virus) is the most fatal disorder for which no complete successful chemotherapy has been developed. The current therapy against AIDS is based on six categories of drugs: nucleoside/ nucleotide reverse transcriptase inhibitor (NRTI's), non-nucleotide reverse transcriptase (NNRTI's), protease inhibitors (PI's), cell entry inhibitors and co-receptor inhibitors (CRI's) and integrase inhibitor (INI's)⁴⁵. Saud *et. al* (2006) synthesized benzothiazole conjugated with 4-nitro imidazole and screened for their in vitro anti-HIV-1 and HIV-2 in human lymphocyte (MT-4) cells⁴⁶ (19) (Figure 13).



2-(2-Methyl-4-nitro-imidazol-1-yl)-benzothiazole
(19)

Figure 13 — BTA as anti-HIV

substituted BTA and were screened for their antihelminthic activity at a conc. of 50,100,150 μ /mL using DMSO as a standard⁵³ (23). Nadkarni *et al.* synthesized substituted phenyl imidazole BTA and showed antihelminthic activity⁵⁴ (24) (Figure 15).

Antitubercular activity

Mycobacterium tuberculosis causes the TB disease and is spread through the air. TB is caused by pathogens and mainly affects lungs. The TB is more common for people suffering from HIV/AIDS⁴⁷. Landge *et al.* (2015) synthesized 2- substituted benzothiazole to exhibit potent anti-mycobacterium activity through specific inhibition of decaprenyl phosphoryl-beta-D-ribose-2'- oxidase (DprE1)⁴⁸ (20). Sangamesh A. Patel *et al.* synthesized Co(I), Ni(II), Mn(III) metal complexes that showed their activity against mycobacterium tuberculosis strain H₃7Rv⁴⁹. Huang *et al.* synthesized 2- methyl BTA analogs depicting anti-TB properties⁵⁰. Palmer *et al.* synthesized BTA derivative having potent greatest activity against M.tuberculosis along with antimicrobial activity against gram positive and gram negative bacteria⁵¹ (22) (Figure 14).

Antihelminthic activity

Helminth parasitism remains an under appreciated scourge of humans in most of the developing world. As individuals are infected with filariae, hookworms, whipworm, large roundworm, or schistosomes which results in chronic, are debilitating morbidity⁵². Reddy D and Sudhakar synthesized thiazolidindione

Antioxidant activity

Antioxidant compounds in food plays an important role as health protecting factors. The main characteristics of antioxidant are its ability to trap free radicals. These free radicals are able to oxidize nucleic acid, proteins, and lipids and initiate degenerative disease. Anion compounds inhibit oxidative mechanism that lead to degenerative diseases⁵⁵. J.Joseph and G. Boomadevi Janaki studied structural characterization of 2-amino BTA which showed their antioxidant activity before forming complex with free ligands⁵⁶ (25) (Figure 16).

Hazra *et al.* (2011) synthesized fluoro benzo pyrazoline derivative and showed their antioxidant activity at 0.01 mm concentration with DPPH method substitution with electron donating group at 4 th position increases the potency⁵⁷ (26) (Figure 17).

Anticonvulsant activity

Epilepsy is a syndrome of different cerebral disorders of the central nervous system and is characterized by paroxysmal, excessive and hyper synchronous discharge of large number of neurons. Data show that only 28-30 % of patients are poorly treated with currently available antiepileptic drugs and these drugs may also cause serious side effects




Figure 14 — Analogues of BTA as antitubercular agent




Figure 15 — Analogues of BTA as antihelminthic agent




Figure 16 — BTA as antioxidant

including ataxia, nausea, mental dulling and hepatotoxicity⁵⁸. Siddique *et al.* synthesized a series of benzothiazoleisothiourea derivative as anticonvulsant agent. The compounds emerged as more active compounds in comparison to phenytoin carbamazepine⁵⁹ (27) (Figure 18).




Figure 17 — Analogues of BTA as antioxidant agent

Liu *et al.* synthesized a series of triazole substituted BTA derivative and showed maximum activity against maximal electric shock (MES) – induced toxic extension⁶⁰ (28). Navale *et al.* synthesized a series of


BTA carbamide and were screened for activity using psychometer seizure test⁶¹ (29). Ajeet, Arvind Kumar synthesized hybrid form of BTA quinazoline derivative and found that they have higher affinity values than gamma aminobutyric acid and is better GABA-A inhibition for anticonvulsant activity⁶² (30) (Figure 19).

Analgesic activity

Ashok Kumar et. al worked on various BTA analog and screened for their analgesic and antibacterial activity⁶³ (31) (Figure 20).


Antimalarial activity

Malaria is one of the most serious global health problems in subtropical and tropical zones of the world. The disease is caused by four species of the plasmodium of which Plasmodium Falciparum is the most virulent and potentially deadly. Most serious issue is that malaria parasites develop resistance to clinically used chemotherapeutic agents such as chloroquine, mefloquine and pyrimethamine⁶⁴. Bowyer et al. synthesized BTA containing compounds by use of scintillation proximity assay and identified activity against both recombinant – N - myristoyl transferase and asexual stages of P. falciparum⁶⁵ (32). Hout .S et al. reported antimalarial activity of




N-(5-Chloro-benzothiazol-2-yl)-2-p-tolylcarbamimidoylsulfanyl-acetamide
(27)


Figure 18 — Analogues of BTA as anticonvulsant agent



7-Butoxy-2H-benzo[4,5]thiazolo[2,3-c][1,2,4]triazol-3-one
(28)



N-Benzothiazol-2-yl-acetamide
(29)



3-Benzothiazol-2-ylmethyl-2-methyl-3H-quinazolin-4-one
(30)

Figure 19 — Analogues of BTA as anticonvulsant agent


2-substituted-6-nitro and 6-amino benzothiazole and their anthranilic acid were carried out on W2 and 3D7 strains of Plasmodium falciparum⁶⁶ (33) (Figure 21).

Antidiabetic activity

Diabetes mellitus is characterized by chronic hyperglycemia and it belongs to a group of metabolic disorder. According to estimation there are 171 million people in world with diabetes. There is thus a growing need for effective therapies to realize optimal glycemic control within the management of diabetes. Navarrete Vazquez et al. prepared ethyl benzothiazoleoxo acetate derivative using one step reaction. The in vitro inhibitory activity of compounds against protein tyrosine phosphatase was evaluated. The compounds are also evaluated for in vivo hypoglycemic activity, shows significant lowering of plasma glucose concentration in acute normal glycemic model and oral glucose tolerance similar to drug glibenzclamide⁶⁷ (34). Jeon et al. (2006) synthesized BTA thiazolidinedione's conjugated with the alkyl groups on exocyclic nitrogen and found the activity against peroxisome activator- γ (PPAR- γ). Compounds containing methyl group on exocyclic nitrogen for PPAR- γ agonist⁶⁸ (35) (Figure 22).

MTP inhibition activity

Chi.B. et al. synthesized triamide BTA derivative. These compounds shown potent entero cyclic specific microsomal triglyceride transfer protein (MTP). Inhabitation of MTP by small molecules lead to a reduction in plasma triglyceride and cholesterol level⁶⁹ (36) (Figure 23).



(31)

Figure 20 — BTA as analgesic




Figure 21 — Analogues of BTA as antimalarial agent




Figure 22 — Analogues of BTA as antidiabetic agent




Figure 23 — BTA as MTP inhibitor

Antidepressant activity


Depression is a serious life threatening illness and is characterized by loss of interest in activities, loss of energy, hypersomnia and thinking for suicide. Wang *et al.* (2014) synthesized BTA containing dihydro-dioxane derivative and evaluated for their binding affinity to serotonin receptor⁷⁰ (37). Several 2-substituted BTA compounds exhibit dual acting

5HT receptor and serotonin transfer inhibitor antidepressant⁷¹ (38) (Figure 24).


Antialzheimer activity

Alzheimer disease is a progressive neuro-degenerative disease characterized by the memory loss, loss of ability to carry out conversation and respond. Amyloid aggregates play an important role in the development of Alzheimer disease, quantification of this amyloid plaque can be detected by Positron Emission Tomography (PET). Ono *et al.* (2009) synthesized the benzothiazole 2- substituted derivative exhibited the beta amyloid imaging probes. Synthesized compounds showed the fluorescence properties and were visualized in human brain⁷² (39) (Figure 25).

Tacrine linked with phenyl BTA three carbon spacers are potent compound for AchE inhibitor at




2,3-Dihydro-benzo[1,4]dioxine-2-carboxylic acid
[2-(4-benzothiazol-2-yl-
piperidin-1-yl)-ethyl]-amide
(37)




1-Benzothiazol-2-yl-5-[4-(4-chloro-phenyl)-piperazin-1-yl]-
pentan-1-one
(38)

Figure 24 — Analogues of BTA as antidepressant agent




3-(6-Dimethylamino-benzothiazol-2-yl)-2-isocyano-acrylonitrile
(39)

Figure 25 — Analogues of BTA as antidepressant agent



N-(4-Benzothiazol-2-yl-phenyl)-2-
(1,2,3,4-tetrahydro-acridin-9-ylamino)-acetamide
(40)

Figure 26 — Analogues of BTA as antialzheimer agent



1-Amino-2-benzothiazol-2-yl-10H-acridin-9-one
(41)

Figure 27 — Analogues of BTA as antileishmanial agent

IC₅₀ value 0.017 microM conc and also showed the AB aggregation activity 51.8% at 20 microM conc⁷³ (40) (Figure 26).

Anti-leishmanial activity

Delmas *et al.* synthesized BTA – acridindione derivative using Ullman reaction and screened their in vitro ant leishmanial activity⁷⁴ (41) (Figure 27).

Acknowledgements

The author sincerely thanks S.M.B.T College of Pharmacy, Nashik, India for their constant support and valuable suggestions in completing this manuscript.

Conflict of Interest

The author declares no conflict of interest.

References

- Sukhbir L, Arora K, Mehta H, Aggarwal A & Yadav M, *Chem Inform*, 42 (2011) 42.
- Patel NB & Shaikh FM, *Sci Pharm*, 78(4) (2010) 753.
- Firdaus UL, Siddiqui N, Sahu M & Alam O, *Eur J Biomed Pharm Sci*, 5(2) (2018) 216.
- Hon S, *Bioorganic Med Chem*, 16 (7) (2008) 3626.
- Razus AC, Birzan L, Surugiu NM, Corbu AC & Chiraleu F, *Dyes Pigments*, 74 (2007) 26.
- Huang S, Hsei I & Chen C, *Bioragnic and Medical Chemistry* vol 14 (2006) 6106.
- Singh M, Kumar S & Mayank S, *Med Chem Res*, 24 (2015).
- Maddili SK, Yandrati LP, Siddam S, Kannekanti VK & Gandham H, *J Photochem Photobiol B: Biol* (2017).
- Akhtar T, Hameed S, Al-Masoudi N, Loddio R, Colla P, *Acta Pharm*, 58 (2008) 135.
- Palmer FJ, Trigg RB, Warrington JV, *J Med Chem*, 14 (1971) 248.
- Burger A, Sawhey SN, *J Med Chem*, 11 (1968) 270.
- Henriksen G, Hauser AI, Westwell AD, Yousefi BH, Schwaiger M & Drzezga A, 50(6) (2007) 24.
- Mathis CA, Wang Y, Holt DP, Huang G, Debnath ML & Klunk WE (2003) 2740.
- Chidrawar AB, 4(4) (2018) 429.
- Papenfuh T, *Eur J Med Chem*, (1987) 528.
- Tokala R, Mahajan S, Kiranmai G & Kumar D, *Bioorg Chem* (2020) 104.
- Okelenberg HI & Marvel CS (1970).
- Fan X, He Y, Wang Y, Xue Z, Zhang X & J. Wang, *Tetrahedron Lett*, 52 (8) (2011) 899.
- A. Ben-allouma, *Molecular Diversity*, 38 (36) (1997), 6395.
- Ali A, Taylor GE, Graham DW, *PCT Int Appl WO* 2001028561 (2001).
- Inamdara SM, Morea VK, Mandal SK, *Tetrahedron Lett*, 54 (2013) 579.

- 21 Caputo R, Ettari R, Calabro ML, Puia G, Ravazzini F & M. Zappala (2013).
- 22 Venkatesh P & Tiwari VS, *Arab J Chem* (2011).
- 23 Mishra R, Tomar I, *Int J Pharm Sci Res, Chem Inform*, 2 (2011) 40.
- 24 Gouveia FL *et al*, 44 (2009) 2038.
- 25 Kumar Verma, Abhay *et al. Int J Pharm Res Dev*, 6(08) (2014) 080–085, doi-10.30750/ijpr.2.3.14
- 26 Sahu PK, Sahu PK, Gupta SK, Thavaselvam D & Agarwal DD, *Eur J Med Chem*, 54 (2012) 366, doi- 10.1016/j.ejmech.2012.05.020.
- 27 Asati V, Sahu NK, Rathore A, Sahu S & Kohli DV, *Arab J Chem* (2011) 1–5, doi- 10.1016/j.arabjc.2011.01.036.
- 28 Haroun M *et al* (2018) 75, doi- 10.2174/1568026618666180206101814
- 29 Ono M, Hayashi S, Kimura H, Kawashima H & Nakayama M, *Bioorg Med Chem*, 17(19) (2009) 7002, doi- 10.1016/j.bmc.2009.08.032
- 30 C. Unger, *Interface Science and Technology*, (1996) 189.
- 31 Tekiner-gulbas CKB, *Med Chem Res*, (2013). doi: 10.1007/s00044-013-0577-5
- 32 Ma H *et al*, *Eur J Med Chem*, (2017). doi: 10.1016/j.ejmech.2017.03.076
- 33 Irfan A *et al*, *J Enzyme Inhib Med Chem*, vol 35(1) (2020) 265, doi- 10.1080/14756366.2019.1698036.
- 34 Xuejiao S, Yong X, Ningyu W, *et al. PLoS One* 2013, 863-900, doi- 10.1371/journal.pone.0063900
- 35 Kumbhare RM, Dadmal T, Kosurkar U, Sridhar V & Rao J V, *Bioorg Med Chem Lett*, 22(1) (2012) 453, doi-10.1016/j.bmcl.2011.10.106
- 36 Arasappan A *et al*, *Bioorg Med Chem Lett*, 22(9) (2015) 3229, doi-10.1016/j.bmcl.2012.03.036
- 37 Colla PLA, *J Enzyme Inhib Med Chem*, 58 (2008) 135.
- 38 Nagarajan SR *et al*, 11 (2003) 4769, doi- 10.1016/j.bmc.2003.07.001
- 39 Verma A & Saraf SK, vol 43 (2008) 897, doi- 10.1016/j.ejmech.2007.07.017
- 40 C. S. Rajput and S. Singhal, *Asian J Management*, (2013).
- 41 Viegas-junior C, Danuello A, Bolzani S, Barreiro EJ, Alberto C & Fraga M (2007) 1829.
- 42 Bele DS & Singhvi I, 1 (4) (2011) 1058.
- 43 Srivastava SK, Yadav R & Srivastava SD, (2004), 399.
- 44 O. A. A. Allah, *Bentham Science Publishers*, 55 (2000) 641.
- 45 Al-talib M, Al-soud YA & Abussaud M, *Arab J Chem*, (2011) doi- 10.1016/j.arabjc.2011.09.003
- 46 Bastian I, Colebuuders R, *Drugs*, 58 (1999) 633, doi:10.1016/j.arabjc.2012.12.009
- 47 Murugan Ket al, *Bioorg Med Chem*, (2015), doi-10.1016/j.bmc.2015.11.017
- 48 D. P. Chemica, 3(3) (2011) 97.
- 49 Q. Huang *et al*, *J Med Chem*, (2009) 6757, doi-10.1021/jm901112f
- 50 R. B. Trigg, *Der Pharma Chemica*, 795 (1) (1971) 248.
- 51 Fatma N, Sharma S & Chatterjee RK, 46 (1989) 311.
- 52 Sudhakar D *et al*, *J Enzyme Inhib Med Chem*, 6(1) (2014) 111.
- 53 Prabhu PP, Pande SS, Dubey RN, Selvam TP & Aamir S, 5(2) (2012) 3830.
- 54 H.Sies, *Oxidants and Antioxidants*, (1996) 291.
- 55 Joseph J & Janaki GB, *JPB*, vol 162 (2016) 86, doi-10.1016/j.jphotobiol.2016.06.030
- 56 Ravibabu V, Janardhan B, Rajitha G & Rajitha B, *Pelagia Research Library*, 4(1) (2013) 79.
- 57 Amnerkar ND & Bhusari KP, *Eur J Med Chem*, 45(1) (2010) 149, doi- 10.1016/j.ejmech.2009.09.037.
- 58 Siddiqui N, Alam S, Sahu M, Naim MJ, Shaharyar M & Alam O, *Bioorg Chem*, (2017) doi- 10.1016/j.bioorg.2017.02.009
- 59 Deng X, Wang S & Quan Z, 3:0 (2014) 268, doi- 10.1002/ardp.201300277
- 60 Kale A, *Med Chem Res*, (2013) 1–6, doi- 10.1007/s00044-012-0434-y.
- 61 Kumar AA, *Amer J Pharmacological Sci*, 1(6) (2013) doi-116.doi.10.12691/ajps-1-6-2.
- 62 Saxena KK, *Int J Pharm Sci*, 5(1) (2010) 67.
- 63 Pudhom K, Kasai K, Terauchi H, Inoue H & Kaiser M, (2006) 14, 8550, doi- 10.1016/j.bmc.2006.08.035
- 64 Bowyer PW *et al*, 180 (2007) 173, doi: 10.1042/BJ20070692
- 65 Gwon S, Lee S, Son Y & Kim S, 13 (9) (2012) 1101, doi: 10.1007/s12221-012-1101-0
- 66 Nagarajan SR *et al*, vol 11 (2011) 4769, doi- 10.1016/j.bmc.2003.07.001.
- 67 Jeon R, Kim Y, Cheon Y & Ryu J, (2006) 394.
- 68 Vu CB *et al*, *Bioorg Med Chem Lett*, 19(5) (2019) 1416, 2009, doi- 10.1016/j.bmcl.2009.01.044
- 69 Zhang C, Xu J, Zhao X & Kang C, 41(4) (2017) 537.
- 70 Zhu XY, Etukala JR, Eyunni SVK, Setola V, Roth BL & Ablordeppey SY, *Eur J Med Chem*, 53 (2012) 124, doi: 10.1016/j.ejmech.2012.03.042
- 71 Ono M, Hayashi S, Kimura H, Kawashima H & Nakayama M, *Bioorg Med Chem*, 17 (2009) 19: 7002, doi- 10.1016/j.bmc.2009.08.032.
- 72 Keri RS, Quintanova C, Marques SM, Esteves AR, Cardoso SM & Santos MA, *Bioorg Med Chem*, (2013) doi-10.1016/j.bmc.2013.05.028
- 73 F. Delmas *et al*, *Eur J Med Chem*, (2004) doi-10.1016/j.ejmech.2004.04.006